Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

02. Juli 2019 08:00 ET | Quelle: Ovid Therapeutics Inc.

Ovid Therapeutics Receives Orphan Drug Designation from the European Commission for OV101 for the Treatment of Angelman Syndrome

NEW YORK, July 02, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
27. Juni 2019 08:00 ET | Quelle: Ovid Therapeutics Inc.

Ovid Therapeutics Initiates Pivotal Phase 3 Clinical Trial in Angelman Syndrome; Multiple Data Readouts Across Rare Neurological Disease Pipeline Expected in 2H 2019 and Early 2020

Phase 3 NEPTUNE Trial of OV101 Expected to Enroll the First Patients in the Third Quarter of 2019; CGI-I Angelman Syndrome Scale will be the Sole Primary Endpoint Ovid to Review NEPTUNE Trial Details...
18. Juni 2019 08:00 ET | Quelle: Ovid Therapeutics Inc.

Ovid Therapeutics to Host R&D Day on June 27, 2019

NEW YORK, June 18, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
07. Mai 2019 08:00 ET | Quelle: Ovid Therapeutics Inc.

Ovid Therapeutics Reports First Quarter 2019 Financial Results

Remains on track for all previously stated milestones expected throughout 2019 The STARS study selected as one of three abstracts featured at the 2019 AAN Top Science Press Conference NEW YORK, May ...
18. April 2019 08:00 ET | Quelle: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the American Academy of Neurology 71st Annual Meeting

Emerging Science platform presentation highlights efficacy and safety data of OV101 in Angelman syndrome from the STARS study Research from Ovid’s Fragile X program shows new insights for outcome...
28. März 2019 08:00 ET | Quelle: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Senior Management Changes to Align Expertise with Advancing Clinical Stage Pipeline

NEW YORK, March 28, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
21. März 2019 08:00 ET | Quelle: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Appointment of Pharmaceutical Veteran, Thomas Perone, as Senior Vice President, General Counsel and Corporate Secretary

NEW YORK, March 21, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
07. März 2019 16:05 ET | Quelle: Ovid Therapeutics Inc.

Ovid Therapeutics Reports Fourth Quarter and Full Year 2018 Financial Results

NEW YORK, March 07, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
04. März 2019 08:00 ET | Quelle: Ovid Therapeutics Inc.

Ovid Therapeutics to Present at the Cowen and Company 39th Annual Healthcare Conference on Monday, March 11

NEW YORK, March 04, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...
20. Februar 2019 09:08 ET | Quelle: Ovid Therapeutics Inc.

Ovid Therapeutics Announces Pricing of $30 Million of Securities in Concurrent Public Offerings of Common and Preferred Stock

NEW YORK, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company committed to developing medicines that transform the lives of people with rare...

Vorherige Seite